高尿酸血症 中国就医指南

Hyperuricemia is a metabolic disorder characterized by elevated serum uric acid (SUA) levels—defined as >6.8 mg/dL (>405 µmol/L) in adults—beyond the physiological saturation threshold for monosodium urate crystallization. It arises from an imbalance between uric acid production and excretion, primarily driven by impaired renal urate clearance (accounting for ~90% of cases) or, less commonly, overproduction due to purine metabolism dysregulation (e.g., PRPS1 mutations, HGPRT deficiency, or high-purine diets). Pathophysiologically, hyperuricemia triggers low-grade systemic inflammation via NLRP3 inflammasome activation, endothelial dysfunction, oxidative stress, and renin-angiotensin system upregulation—linking it mechanistically to hypertension, chronic kidney disease (CKD), insulin resistance, cardiovascular disease, and gout. Epidemiologically, prevalence has risen globally alongside urbanization and dietary shifts: current estimates indicate ~14–24% of adults in China have hyperuricemia, with higher rates among men (20–30%) than women (10–15%), and sharp increases after age 40. Key modifiable risk factors include obesity (especially abdominal adiposity), excessive alcohol intake (particularly beer and spirits), high-fructose beverages, red meat and seafood consumption, diuretic use (e.g., thiazides), chronic kidney disease, metabolic syndrome, and hypothyroidism. Non-modifiable risks include male sex, aging, genetic predisposition (e.g., SLC2A9, ABCG2 variants), and familial history. Importantly, hyperuricemia is often asymptomatic for years—yet persistent elevation (>7 mg/dL) significantly increases lifetime gout risk (up to 20% at 5 years, >50% at 20 years) and accelerates CKD progression. Beyond physical morbidity, it substantially impairs quality of life: patients report fatigue, joint stiffness, sleep disruption, anxiety about gout flares, reduced work productivity, dietary restrictions causing social isolation, and long-term concerns about kidney failure or cardiovascular events. Early detection and individualized management—including lifestyle modification, uricosurics (e.g., benzbromarone), or xanthine oxidase inhibitors (e.g., febuxostat, allopurinol)—are critical not only to prevent gout but also to mitigate multisystem end-organ damage. Rheumatology and immunology departments play a central role in diagnosis, risk stratification (e.g., 24-hour urinary uric acid testing, renal function assessment), and longitudinal care, especially given the frequent comorbidity with autoimmune rheumatic diseases such as psoriatic arthritis and lupus nephritis.

# 高尿酸血症治疗方案与费用明细（风湿免疫科）

一、非手术/保守治疗方案

适用人群：无痛风发作史、血尿酸＜540 μmol/L、无肾结石或肾功能损害者。

• •生活方式干预（免费–200元/月）：营养科门诊指导（150–300元/次）、运动处方（含体成分分析，200元/次）
• •基础药物治疗：

• •必要检查费：血尿酸+肝肾功+尿常规+泌尿系超声（420–680元/次）

二、药物强化/联合治疗方案

适用人群：反复痛风发作、血尿酸＞540 μmol/L、合并高血压/慢性肾病者。

• •联合降尿酸（如别嘌醇+小剂量秋水仙碱预防）：药物费300–650元/月
• •血尿酸动态监测（每2–4周）：生化检测180元/次
• •风湿免疫科随访门诊（含评估与调药）：普通号30元/次，专家号50–100元/次

三、特殊复杂/并发症治疗

适用人群：痛风石沉积、慢性尿酸性肾病（eGFR＜60 mL/min/1.73m²）、难治性高尿酸血症。

• •尿酸酶类药物（培格洛替酶）：仅限三甲医院风湿科使用，单次静脉输注费用12,800–15,600元（含药费、输注监护、过敏预处理）
• •合并肾结石需泌尿外科协同管理：体外冲击波碎石（ESWL）单次2,200–3,500元

四、方案快速选择指南

• •预算有限/初诊患者：首选生活方式干预+国产别嘌醇+基础检查（首月总费用约800–1,200元）
• •中等预算/反复发作者：非布司他+专家随访+季度监测（月均支出500–900元）
• •高需求/难治性患者：培格洛替酶联合多学科管理（单疗程3–6次，总费用约4万–9万元）